Wednesday, April 6, 2011
Neurocrine Biosciences Inc., of San Diego, completed dosing and preliminary assessment of its initial cohort of patients in an open-label, Phase IIa trial of NBI-98854 for tardive dyskinesia. NBI-98854 is a vesicular monoamine transporter 2 inhibitor (VMAT2). After 12 days of treatment with the drug, test subjects showed improvement in the abnormal hyperkinetic movements caused by tardive dyskinesia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.